bempikibart   Click here for help

GtoPdb Ligand ID: 13725

Synonyms: ADX-914 | ADX914
Immunopharmacology Ligand
Compound class: Antibody
Comment: Bempikibart (ADX-914; Q32 Bio) is a fully human anti-IL-7 receptor alpha (IL-7Rα) monoclonal antibody [1]. It was designed for potential disease-modifying anti-inflammatory action in autoimmune conditions. Bempikibart blocks IL-7 and thymic stromal lymphopoietin (TSLP) from binding to the common IL-7Rα subunit of their endogenous receptors, thus reducing receptor activation and re-regulating immune homeostasis.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
Binding potency provided from patent WO2020154293A1 [1] pertains to the claimed 'Antibody A' which has identical heavy and light chain amino acid sequences as provided in the bempikibart INN record. 'Antibody A' has no agonist activity at the IL-7 receptor in vitro [1].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-7 receptor subunit α Hs Antibody Binding 8.7 – 9.0 pEC50 - 1
⤷ pEC50 8.7 – 9.0 (EC50 2x10-9 – 1x10-9 M) [1]
Description: Binding potency for IL-7 receptor on isolated human CD8+ve T cells